Changes in biomarker expression in the development of prostatic adenocarcinoma

Biotechnic and Histochemistry

Volumn 72, Issue 2, 1997, Pages 86-95

  Myers, Russell B ^a   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

biomarkers; diagnosis; early detection; prostatic intraepithelial neoplasia (PIN)

Indexed keywords

CANCER SURVIVAL; CARCINOMA IN SITU; CONFERENCE PAPER; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY;

EID: 0030965725     PISSN: 10520295     EISSN: None     Source Type: Journal    
DOI: 10.3109/10520299709082217     Document Type: Conference Paper

References (68)

1. Boag, A. H. and Young, I. D. 1994. Increased expression of the 72-KD type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am. J. Pathol. 144: 585-591.
2. Bonkhoff, H. and Remberger, K. 1993. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic prostate. Virchows Arch. (A) 422: 35-38.
3. Bonkhoff, H., Stein, U. and Remberger, K. 1994a. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24: 114-118.
4. Bonkhoff, H., Stein, U. and Remberger, K. 1994b. Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate. Simultaneous demonstration of cell specific epithelial markers. Human Pathol. 25: 42-46.
5. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Allred, D. G. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53: 3369-3373.
6. Bostwick, D. G. and Brawer, M. K. 1987. Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 59: 788-794.
7. Bostwick, D. G. 1992. Prostatic intraepithelial neoplasia (PIN): current concepts. J. Cell. Biochem. (Suppl.) 16H: 10-19.
8. Bostwick, D. G., Dousa, M. K., Crawford, B. G. and Wollan, P. C. 1994. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Surg. Pathol. 18: 1240-1246.
9. Bostwick, D. G., Pacelli, A. and Lopez-Bettran, A. 1996. Molecular biology of prostatic intraepithelial neoplasia. Prostate 29: 117-134.
10. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M. L., Kmiecik, T. E., Vande Woude, G. F. and Aaronson, S. A. 1991. Identification of the hepatocytic growth factor receptor as the c-met protooncongene product. Science 251: 802-804.
11. Brawer, M. K., Peehl, D. M., Stamey, T. A. and Bostwick, D. G. 1985. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 45: 3663-3667.
12. Brenner, P. C., Rettig, W. J., Sanz-Moncasi, M. P., Reuter, V., Aprikian, A., Old, L. J., Fair, W. R. and Garin-Chesa, P. 1995. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J. Urol. 153: 1575-1579.
13. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S. and Buttyan, R. 1993. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol. 143: 390-400.
14. di Sant' Agnese, P. A. 1992a. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70: 254-268.
15. di Sant' Agnese, P. A. 1992b. Neuroendocrine differentiation in human prostatic carcinoma. Human Pathol. 23: 287-296.
16. Emmert-Buck, M. R., Vocke, C. D., Pozzatti, R. O., Duray, P. H., Jennings, S. B., Florence, C. D., Zhuang, Z., Bostwick, D. G., Liotta, L. A. and Linehan, W. M. 1995. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 53: 2959-2962.
17. English, H. F., Santen, R. J. and Issacs, J. T. 1987. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11: 229-242.
18. Fiorelli, G., de Bellis, A., Longo, A., Giannini, S., Natali, A., Constantini, A., Vanelli, G. B. and Serio, M. 1991. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization and their modulation by chronic treatment with gonadotropin releasing hormone analog. J. Clin. Endocrinol. Metab. 77: 740-746.
19. Giannulis, I., Montironi, R., Gulluzzi, C. M., De Nictolis, M. and Dlamanti, L. 1993. Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN). Anticancer Res. 13: 2447-2452.
20. neu) in prostate tumors: an immunohistochemical study. Prostate 23: 329-336.
21. Gould, V. E., Doljanskaia, V., Gooch, G. and Bostwick, D. G. 1996. Immunolocalization of glycoprotein A-80 in prostatic hyperplasia, dysplasia and carcinoma. Modern Pathol. 9: 73A.
22. Hailat, N., Keim, D. R., Melhem, R. F., Zhu, X. X., Eckerson, C., Brodeur, G. M., Reynolds, C. P., Seeger, R. C., Lottspeich, F. and Strahler, J. R. 1991. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc amplification. J. Clin. Invest. 88: 341-345.
23. Hakomori, S. I. 1989. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res. 52: 257-331.
24. Harper, M. E., Goddard, E., Glyne-Jones, E., Wilson, D. W., Price-Thomas, M., Peeling, W. B. and Friffiths, K. 1993. An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate 23: 9-23.
25. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava S. 1995. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154: 414-421.
26. Hennessy, C., Henry, J. A., May, F. E., Westly, B. R., Angus, B. and Lennard, T. W. 1991. Expression of the antimetastatic gene in human breast cancer: an association with good prognosis. J. Natl. Cancer Inst. 83: 281-285.
27. Hughes, J. H., Cohen, M. B. and Robinson, R. A. 1995. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma. Modern Pathol. 8: 462-466.
28. Ibrahim, G. K., Kems, B. M., MacDonald, J. A., Ibrahim, S. N., Kinney, R. B., Humphrey, P. A. and Robertson, C. N. 1993. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J. Urol. 149: 170-173.
29. Igawa, M., Rukstalis, D. B., Tanabe, T. and Chodak, G. W. 1994. High levels of nm23-H1 are related to cell proliferation in prostatic cancer. Cancer Res. 54: 1313-1318.
30. Jorgensen, T., Berner, A., Kaalhus, O., Tueter, K. J., Danielsen, H. E. and Bryne, M. 1995. Up-regulation of the oligosaccharide sialyl Lewis X: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 55: 1817-1819.
31. Leave, I., McNeal, J. E., Kwan, P. W.-L., Komminoth, P. and Merk, F. B. 1996. Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29: 137-145.
32. Levine, A. J., Momand, J. and Finaly, C. A. 1991. the p53 tumor suppressor gene. Nature 351: 453-456.
33. Lyne, J. C., Melhem, M. F., Finley, G. G., Deng, D. and Salup, R. R. 1996. Expression of the HER family of receptors and their ligand neu differentiation factor in human prostate specimens. Proc. Am. Assoc. Cancer Res. 36: 243A.
34. Matsumoto, K., Tajima, H. and Nakamura, T. 1991. Hepatocytic growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem. Biophys. Res. Commun. 176: 45-49.
35. Maygarden, S. J., Strom, S. and Ware, J. L. 1992. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch. Pathol. Lab. Med. 166: 269-173.
36. Maygarden, S. J., Novotny, D. B., Moul, J. W., Bae, V. L. and Ware, J. L. 1994. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Modern Pathol. 7: 930-936.
37. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Lagothetis, C., Chung, L. W. K., Hsieh, J.-T., Tu, S.-M. and Campbell, M. L. 1992. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen independent prostate cancer. Cancer Res. 52: 6940-6944..
38. McNeal, J. E., Alroy, J., Leau, I., Redwine, E. A., Freiha, F. S. and Stamey, T. A. 1988. Immunohistochemical evidence for impaired cell differentiation of the premalignant phase of prostate carcinogenesis. Am. J. Clin. Pathol. 90: 23-32.
39. McNeal, J. E., Haillot, O. and Yemoto, C. 1995. Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate 27: 258-268.
40. Montironi, R., Galluzzi, C. M., Diamanti, L., Glannulis, I., Pisani, E. and Scarpelli, M. 1993. Prostatic intraepithelial neoplasia. Expression and localization of proliferating cell nuclear antigen (PCNA) in epithelial, endothelial and stromal nuclei. Virchows Archiv. A. Pathol. Anat. 422: 185-192.
41. Montone, K. T. and Tomaszewski, J. E. 1993. In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J. Clin. Lab. Anal. 7: 188-195.
42. Myers, R. B., Kulow, J. E. and Grizzle, W. E. 1993. Expression of transforming growth factor alpha, epidermal growth factor and the epidermal growth factor receptor in benign prostatic hyperplasia and adenocarcinoma of the prostate. Modern Pathol. 6: 733-737.
43. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst. 86: 1140-1145.
44. Myers, R. B., Oelschlager, D., Srivastava, S. and Grizzle, W. E. 1994b. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 25: 243-248.
45. Myers, R. B., Schlom, J., Srivastava, S. and Grizzle, W. E. 1995a. Expression of tumor associated glycoprotein-72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Modern Pathol. 8: 260-265.
46. Myers, R. B., Srivastava, S. and Grizzle, W. E. 1995b. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J. Urol. 153: 1572-1574.
47. Myers, R. B., Lampejo, O., Herrera, G. A., Srivastava, S., Oelschlager, D., Brown, D. A., Waterbor, J. W. and Grizzle, W. E. 1995c. TGFα expression is a relatively late event in the progression of prostatic adenocarcinoma. J. Urol. Pathol. 3: 195-203.
48. Myers, R. B., Srivastava, S., Oelschlager, D. K., Brown, D. and Grizzle, W. E. 1996a. Expression of the nm23-H1 in prostatic intraepithelial neoplasia and adenocarcinoma. Hum. Pathol. 27: 1021-1024.
49. Myers, R. B., Oelschlager, D. K., Poczatek, R. B., Srivastava, S. and Grizzle, W. E. 1996b. The expression of the androgen regulated enzyme fatty acid synthetase in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. 10th International Congress of Endocrinology. Vol. 1. p. 158A.
50. Nagle, R. B., Brawer, M. K., Kittelson, J. and Clark, V. 1991. Phenotypic relationships of prostatic intraepithelial neoplasia to prostatic carcinoma. Am. J. Pathol. 138: 119-128.
51. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C. and Conti, C. J. 1993. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85: 1657-1669.
52. Nuti, M., Teramoto, Y. A., Mariani-Constantini, R., Hand, P. H., Colcher, D. and Schlom, J. 1982. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer 29: 539-545.
53. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A. 1996. Cancer Statistics, 1996. Ca Cancer J. Clin. 65: 5-27.
54. Perlman, E. J. and Epstein, J. I. 1990. Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am. J. Surg. Pathol. 14: 810-818.
55. Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C. and Chung, L., W., K. 1995. C-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154: 293-298.
56. Ruizeveld de Winter, J. A., Trapman, J., Vermey M., Mulder, E., Zegers, N. D. and Van der Kwast, Th. H. 1991. Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem. 39: 927-936.
57. Scher, H. I., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelsohn, J. and Cordon-Cardo, C. 1995. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin. Cancer Res. 1: 545-550.
58. Sentinelli, S. 1993. Mucins in prostatic intraepithelial neoplasia and prostatic carcinoma. Histopathology 22: 271-274.
59. Sherwood, E. R., Theyer, G., Steiner, G., Berg, L. A., Kozlowski, J. M. and Lee, C. 1991. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelial of the human prostate. Prostate 18: 303-314.
60. Siadat-Pajouh, M., Nagle, R. B., Breathnach, R., Finch, J. S., Brawer, M. K. and Bowden, G. T. 1991. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 117: 144-150.
61. Steeg, P. S., Bevilacqua, G., Kopper, L., Thorgeirsson, U. P., Talmadge, J. E., Liotta, L. A. and Sobel, M. E. 1988. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 80: 200-204.
62. Stramignoni, D., Bowen, R., Atkinson, B. F. and Schlom, J. 1983. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int. J. Cancer 31: 543-552.
63. Takada, A., Ohmori, K., Yoneda, T., Tsuyuoka, K., Hasegawa, A., Kiso, M. and Kannagi, R. 1993. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 53: 354-361.
64. Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M. and McGuire, W. L. 1990. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med. 322: 297-300.
65. Theisinger, B., Seib, T., Seitz, G., Huwer, H., Zang, K. D., Welter, C. and Dooley, W. C. 1993. High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int. J. Cancer 55: 375-379.
66. Turbat-Herrera, E. A., Herreram, G. A., Gore, I., Lott, R. A., Grizzle, W. E. and Bonnin, J. M. 1988. Neuroendocrine differentiation in prostatic carcinomas. Arch. Pathol. Lab. Med. 112: 1100-1105.
67. Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T. and Iosala, J. 1992. Small subgroup of aggressive, highly proliferative prostatic carcinomas denned by p53 accumulation. J. Natl. Cancer Inst. 84: 883-887.
68. Wernert, N., Seitz, G. and Achtstatter, T. H. 1987. Immunohistochemical investigation of different cytokeratins in the prostate from the fetal period up to adulthood. Pathol. Res. Pract. 138: 119-128.